國立虎尾科技大學 |

Lung Cancer = New Understandings and Therapies /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Lung Cancer/ edited by Anne C. Chiang, Roy S. Herbst.
其他題名:	New Understandings and Therapies /
其他作者:	Herbst, Roy S.
面頁冊數:	VI, 264 p. 17 illus., 16 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology. -
電子資源:	https://doi.org/10.1007/978-3-030-74028-3
ISBN:	9783030740283

Lung Cancer = New Understandings and Therapies /
Lung CancerNew Understandings and Therapies /[electronic resource] :edited by Anne C. Chiang, Roy S. Herbst. - 1st ed. 2021. - VI, 264 p. 17 illus., 16 illus. in color.online resource. - Current Cancer Research,2199-2592. - Current Cancer Research,.

Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

ISBN: 9783030740283

Standard No.: 10.1007/978-3-030-74028-3doiSubjects--Topical Terms:

593951
Oncology.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Lung Cancer = New Understandings and Therapies /
LDR:02684nam a22004095i 4500 001 1054604
003 DE-He213
005 20210930163851.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030740283 $9 978-3-030-74028-3
024 7 $a 10.1007/978-3-030-74028-3 $2 doi
035 $a 978-3-030-74028-3
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Lung Cancer $h [electronic resource] : $b New Understandings and Therapies / $c edited by Anne C. Chiang, Roy S. Herbst.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2021.
300 $a VI, 264 p. 17 illus., 16 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Current Cancer Research, $x 2199-2592
505 0 $a Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
520 $a Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
650 2 4 $a Oncology. $3 593951
650 2 4 $a Molecular Medicine. $3 668353
650 1 4 $a Cancer Research. $3 668358
650 0 $a Oncology . $3 1253469
650 0 $a Molecular biology. $3 583443
650 0 $a Cancer research. $3 1253664
700 1 $a Herbst, Roy S. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1359694
700 1 $a Chiang, Anne C. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1359693
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030740276
776 0 8 $i Printed edition: $z 9783030740290
776 0 8 $i Printed edition: $z 9783030740306
830 0 $a Current Cancer Research, $x 2199-2584 $3 1257028
856 4 0 $u https://doi.org/10.1007/978-3-030-74028-3
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)